Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Core Scientific filings document the company’s public reporting for its common stock and Nasdaq-listed warrants, including CORZZ tranche 2 warrants exercisable for common stock at a $0.01 exercise price. The records identify Core Scientific as a digital infrastructure business with bitcoin self-mining, digital asset hosting and high-density colocation operations.
Recent 8-K filings cover operating and financial results, Regulation FD materials, material definitive agreements, securities registered under Section 12(b), senior secured notes due 2031, capital-structure disclosures, subsidiary financing arrangements and governance matters such as officer appointments and compensation arrangements.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
Nygaard James P Jr reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. executive vice president and chief financial officer James P. Nygaard Jr. reported receiving a grant of 120,074 shares of Common Stock in the form of restricted stock units as equity compensation.
According to the filing, one-third of these RSUs will vest on March 15, 2027, and the remaining two-thirds will vest in eight substantially equal quarterly installments after that date, as long as he continues providing service to the company on each vesting date. Following this award, he holds 1,043,056 shares of Common Stock directly.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
DUCHENE TODD M reported acquisition or exercise transactions in this Form 4 filing.
Core Scientific, Inc. reported that officer Todd M. Duchene received an annual grant of 138,547 shares of common stock in the form of restricted stock units on May 20, 2026, at no purchase price. One-third of these RSUs will vest on March 15, 2027, with the remaining two-thirds vesting in eight substantially equal quarterly installments thereafter, as long as he continues serving the company on each vesting date. Following this equity award, Duchene directly holds 2,098,895 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock in open-market transactions on May 18, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025.
The sales occurred in two tranches: 9,600 shares at a weighted average price of $23.1244 per share, within a range of $22.66 to $23.62, and 400 shares at a weighted average price of $23.7575, within a range of $23.69 to $23.82. Following these transactions, he directly owns 1,960,348 shares of Common Stock.
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Valiant Capital Management filed an amendment on Schedule 13G reporting beneficial ownership of 16,213,103 shares of Core Scientific, Inc. common stock, equal to 5.1% of the class. The percentage is calculated using 317,885,292 shares outstanding as of May 1, 2026. The filing states the holding is reported jointly by Valiant Capital Management, L.P., Valiant Capital Management, LLC and Christopher R. Hansen, with shared voting and shared dispositive power over the 16,213,103 shares. The reporting persons disclaim membership in a group and disclaim beneficial ownership except to the extent of pecuniary interest. Signatures are dated May 15, 2026.
Core Scientific, Inc. - Joint Schedule 13G/A discloses passive ownership by Citadel-related entities and Kenneth Griffin. The filing reports that Citadel Securities LLC may be deemed to beneficially own 9,357,746 shares (3.0%) and that Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin may each be deemed to beneficially own 12,792,480 shares (4.1%) based on 315,596,127 Shares outstanding as of March 23, 2026. The statement describes shared voting and dispositive power and notes certain shares issuable upon conversion of warrants.
Core Scientific, Inc. - Joint Schedule 13G/A discloses passive ownership by Citadel-related entities and Kenneth Griffin. The filing reports that Citadel Securities LLC may be deemed to beneficially own 9,357,746 shares (3.0%) and that Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin may each be deemed to beneficially own 12,792,480 shares (4.1%) based on 315,596,127 Shares outstanding as of March 23, 2026. The statement describes shared voting and dispositive power and notes certain shares issuable upon conversion of warrants.
Core Scientific, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on directors, executive compensation and the independent auditor. Five directors were elected, including Adam Sullivan with 217,650,785 votes for and 2,469,826 withheld, and Elizabeth Crain with 215,074,279 for and 5,046,332 withheld.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 138,785,477 votes for, 79,166,695 against and 2,168,439 abstentions. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,833,296 votes for, 313,161 against and 1,752,370 abstentions.
Core Scientific, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders voted on directors, executive compensation and the independent auditor. Five directors were elected, including Adam Sullivan with 217,650,785 votes for and 2,469,826 withheld, and Elizabeth Crain with 215,074,279 for and 5,046,332 withheld.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 138,785,477 votes for, 79,166,695 against and 2,168,439 abstentions. They also ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 262,833,296 votes for, 313,161 against and 1,752,370 abstentions.
Core Scientific, Inc. ownership disclosure: a group of affiliated broker‑dealers led by Susquehanna entities reports beneficial ownership of 14,631,891 shares, representing 4.6% of the class. The filing states 315,594,802 Shares outstanding as of March 23, 2026. The reported holdings include option and warrant positions: 12,963,500 options and various warrants and options held across the reporting entities. The filing is a joint Schedule 13G/A by G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC, and includes a joint filing agreement.
Core Scientific, Inc. ownership disclosure: a group of affiliated broker‑dealers led by Susquehanna entities reports beneficial ownership of 14,631,891 shares, representing 4.6% of the class. The filing states 315,594,802 Shares outstanding as of March 23, 2026. The reported holdings include option and warrant positions: 12,963,500 options and various warrants and options held across the reporting entities. The filing is a joint Schedule 13G/A by G1 Execution Services, LLC; SIG Brokerage, LP; Susquehanna Investment Group; and Susquehanna Securities, LLC, and includes a joint filing agreement.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.
Core Scientific, Inc. officer Todd M. Duchene reported selling 10,000 shares of Common Stock on May 11, 2026 in open-market transactions. The sales occurred in two blocks at weighted average prices of $22.8162 and $23.3916 per share. The filing states the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily. After these sales, Duchene continues to hold a substantial direct equity position in the company, so the activity represents a small portion of his overall holdings.
Core Scientific, Inc. executive Ray Jorge L., the Chief Accounting Officer, has reported his initial beneficial ownership of company equity on a Form 3. The filing shows direct ownership of 37,998 shares of Common Stock. A related footnote describes this as a restricted stock unit grant, with one-third vesting on March 5, 2027 and the remaining two-thirds vesting in eight substantially equal quarterly installments afterward, as long as he continues providing service on each vesting date.
Core Scientific, Inc. executive Ray Jorge L., the Chief Accounting Officer, has reported his initial beneficial ownership of company equity on a Form 3. The filing shows direct ownership of 37,998 shares of Common Stock. A related footnote describes this as a restricted stock unit grant, with one-third vesting on March 5, 2027 and the remaining two-thirds vesting in eight substantially equal quarterly installments afterward, as long as he continues providing service on each vesting date.
Core Scientific, Inc. reported sharply higher Q1 2026 revenue of $115.2 million, up from $79.5 million a year earlier, driven mainly by high-density colocation services. Colocation revenue rose to $77.5 million with a 57% gross margin, reflecting rapid expansion of AI and HPC-focused data centers.
The company recorded a net loss of $347.2 million, compared with net income of $576.3 million in Q1 2025, primarily due to $266.5 million of non-cash impairment charges on mining equipment and infrastructure as it pivots away from bitcoin self-mining. Digital asset self-mining revenue fell to $30.1 million and generated a negative gross margin.
Cash, cash equivalents and restricted cash increased to $1.15 billion, largely from a new $1.0 billion term loan facility, later refinanced via a $3.30 billion 7.75% senior secured notes issuance. Total liabilities reached $4.38 billion, and stockholders’ deficit widened to $1.31 billion. Deferred revenue climbed to $654.2 million, reflecting substantial pre-funded colocation build-outs and long-term contracts.
Core Scientific, Inc. reported sharply higher Q1 2026 revenue of $115.2 million, up from $79.5 million a year earlier, driven mainly by high-density colocation services. Colocation revenue rose to $77.5 million with a 57% gross margin, reflecting rapid expansion of AI and HPC-focused data centers.
The company recorded a net loss of $347.2 million, compared with net income of $576.3 million in Q1 2025, primarily due to $266.5 million of non-cash impairment charges on mining equipment and infrastructure as it pivots away from bitcoin self-mining. Digital asset self-mining revenue fell to $30.1 million and generated a negative gross margin.
Cash, cash equivalents and restricted cash increased to $1.15 billion, largely from a new $1.0 billion term loan facility, later refinanced via a $3.30 billion 7.75% senior secured notes issuance. Total liabilities reached $4.38 billion, and stockholders’ deficit widened to $1.31 billion. Deferred revenue climbed to $654.2 million, reflecting substantial pre-funded colocation build-outs and long-term contracts.